


Pembrolizumab KEYNOTE-006

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Long term plateau in the survival curve

Pembrolizumab KEYNOTE-006

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers
 Therapeutic Indication: Treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma
 Experimental Arm: Pembrolizumab
 Control Arm: Ipilimumab

